Table 4.

Single-factor analysis of PFS and OS in the two groups of patients

	n	PFS (months) 95% CI	P	OS (months) 95% CI	P
Ages (years)			0.676		0.858
≥ 50	45	3.60(3.01–4.19)		8.70 (4.42–12.98)
< 50	63	4.00(3.42–4.58)		10.00 (8.52–11.48)
Recurrent lesions			0.034		0.009
In pelvic cavity	27	6.3(2.48–11.51)		15.8(12.53–19.07)
Out of pelvis	81	3.60(2.95–4.25)		9.00(7.10–10.90)
CA125 level			0.001		0.038
Decline	38	7.0(3.86–10.15)		12.00(7.63–16.37)
Poor decline	70	3.0(1.91–4.09)		9.30(5.10–13.51)
Adverse reactions			0.089		0.540
≥ 3	27	3.60(2.94–4.26)		9.30(6.55–12.05)
None or ≤ 2	81	4.20(2.43–5.97)		10.60(7.95–13.25)
FIGO Stage			0.912		0.667
IIIC	76	3.80(3.43–4.17)		12.70(4.47–20.93)
IV	32	3.30(1.84–4.76)		9.70(7.87–11.53)
Treatment course			0.000		0.000
≥ 3 cycles	58	6.2(4.02–8.38)		14.00(8.78–19.22)
< 3 cycles	50	2.2(1.87–2.53)		5.10(2.87–7.33)
Surgery again after recurrence			0.046		0.065
Yes	37	6.0(3.68–8.32)		14.0(9.28–18.72)
No	71	3.6(2.69–4.51)		9.00(7.15–10.85)
Histology			0.939		0.886
Serous	82	3.80(3.41–4.06)		10.50(8.74–12.26)
Non-serous	26	3.80(1.93–5.67)		9.30(7.12–11.48)
Ascites			0.008		0.031
Yes	38	2.2(1.41–2.98)		6.10(2.32–9.88)
No	70	4.2(2.47–5.93)		10.7(8.40–13.00)
Basic illness			0.163		0.729
Yes	41	3.60(2.74–4.46)		9.30(6.94–11.66)
No	67	4.00(3.46–4.54)		10.70(7.75–13.65)